Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma
- PMID: 17929118
- DOI: 10.1007/s10147-007-0701-y
Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma
Abstract
Background: The prognosis of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) in the main trunk or the first branch is very poor.
Methods: Radiotherapy (RT) to PVTT was followed by hepatectomy within 2 weeks. The dose used was 30-36 Gy, in 10-12 fractions, for 15-20 days. The efficacy of preoperative RT to PVTT in the main trunk or first branch was evaluated by comparing results in patients who underwent hepatectomy (group R; n = 15) with preoperative RT and those without preoperative RT (group N; n = 28).
Results: The 1-, 3-, and 5-year survival rates in group R were 86.2%, 43.5%, and 34.8%, respectively, while these values in group N were 39.0%, 13.1%, and 13.1%, respectively. The survival curve of group R was significantly better than that of group N (P = 0.0359). In group R, five (83.3%) of six patients whose tumor thrombus was completely necrosed (based on pathological examination) and whose follow-up period was over 2 years survived for more than 2 years. Female sex (P = 0.0066), multiple tumors (P = 0.0369), and absence of preoperative RT (P = 0.0359) were ranked as significant factors for a poor prognosis by univariate analysis. Multivariate analysis revealed absence of preoperative RT and female sex to be significant factors for a poor prognosis.
Conclusion: Preoperative RT to PVTT in the main trunk or first branch improved the prognosis of patients with HCC with PVTT, and could be a promising new modality in the treatment of these patients.
Similar articles
-
Successful preoperative treatment for hepatocellular carcinoma with tumor thrombus in the major portal branch by three-dimensional conformal radiation therapy--two case reports.Hepatogastroenterology. 2005 Mar-Apr;52(62):343-7. Hepatogastroenterology. 2005. PMID: 15816431
-
Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.J Clin Oncol. 2019 Aug 20;37(24):2141-2151. doi: 10.1200/JCO.18.02184. Epub 2019 Jul 8. J Clin Oncol. 2019. PMID: 31283409 Free PMC article. Clinical Trial.
-
Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.World J Gastroenterol. 2015 Jan 7;21(1):246-53. doi: 10.3748/wjg.v21.i1.246. World J Gastroenterol. 2015. PMID: 25574098 Free PMC article.
-
Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis.World J Gastroenterol. 2016 Aug 14;22(30):6851-63. doi: 10.3748/wjg.v22.i30.6851. World J Gastroenterol. 2016. PMID: 27570422 Free PMC article. Review.
-
The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus.Int J Surg. 2015 Aug;20:8-16. doi: 10.1016/j.ijsu.2015.05.009. Epub 2015 May 27. Int J Surg. 2015. PMID: 26026424 Review.
Cited by
-
Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma.World J Surg Oncol. 2012 Jun 14;10:107. doi: 10.1186/1477-7819-10-107. World J Surg Oncol. 2012. PMID: 22697061 Free PMC article.
-
Conversion therapy of a giant hepatocellular carcinoma with portal vein thrombus and inferior vena cava thrombus: A case report and review of literature.World J Clin Cases. 2024 Jun 6;12(16):2847-2855. doi: 10.12998/wjcc.v12.i16.2847. World J Clin Cases. 2024. PMID: 38899296 Free PMC article.
-
Efficacy of radiotherapy in combined treatment of hepatocellular carcinoma patients with portal vein tumor thrombus: a real-world study.BMC Surg. 2024 Feb 14;24(1):54. doi: 10.1186/s12893-024-02334-1. BMC Surg. 2024. PMID: 38355536 Free PMC article.
-
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.EClinicalMedicine. 2023 Dec 12;67:102367. doi: 10.1016/j.eclinm.2023.102367. eCollection 2024 Jan. EClinicalMedicine. 2023. PMID: 38169778 Free PMC article.
-
Clinicopathological predictors of poor survival and recurrence after curative resection in hepatocellular carcinoma without portal vein tumor thrombosis.Pathol Oncol Res. 2015 Jan;21(1):131-8. doi: 10.1007/s12253-014-9798-2. Epub 2014 Jun 8. Pathol Oncol Res. 2015. PMID: 24908141
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical